Global Epigenetics Market Will Grow to USD 0.8 Billion by 2028, at a CAGR of 13.1%

2022-02-14 12:23:27 UTC | Healthcare & Pharmaceuticals
Global Epigenetics Market Will Grow to USD 0.8 Billion by 2028, at a CAGR of 13.1%

Market Synopsis:

Global Epigenetics market is valued at USD 0.8 Billion in 2021 and is projected to attain a value of USD 3.0 Billion by 2028 at a CAGR of 13.1% during the forecast period, 2022–2028. The increased prevalence of cancer and other chronic diseases, as well as the ageing population, are expected to drive market expansion. The presence of institutions like the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) is helping the industry flourish. These groups advocate for funding and support for Epigenetics -related R&D and product development. The National Institutes of Health has a common fund epigenomics initiative that actively encourages innovative Epigenetics research around the world.

COVID-19's increased prevalence is expected to have an impact on market growth over the projection period. The COVID-19 dilemma has had a significant and immediate impact on the healthcare industry. Because of the unexpected impact on the supply chain and the limits imposed on manufacturing and supply operations during the early stages of the Corona virus pandemic, most pharmaceutical and nutraceutical companies suffered a minor loss in the first few quarters. COVID-19, on the other hand, has raised demand for Epigenetics , and some important players have seen favorable sales growth as a result of the increased demand.

Rising Cancer Prevalence

There has been a huge increase in the number of people diagnosed with cancer around the world. According to WHO forecasts, the number of cancer patients is predicted to rise from 14.1 million in 2012 to 19.3 million by 2025. Cancer formation and progression are linked to Epigenetics , alterations such as DNA methylation dysregulation. Epigenetics opens up new avenues for developing therapeutic treatments to counteract cancer deregulation. Several cancer research studies using Epigenetics , approaches are now underway, and significant funding is being allocated to these investigations.

Market Segmentation:

The Global Epigenetics Market can be segmented by product type, into Reagents & Kits, Instruments and Others. By Application into Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases, and Others. Based on Technology into DNA Methylation, Histone Methylation, Histone Acetylation, Large non - coding RNA, MicroRNA modification, Chromatin structures. Based on Region, the Market is segmented into North America, Europe, Asia Pacific, Latin America And Middle East & Africa.

Read Full Report @ https://www.vantagemarketresearch.com/industry-report/epigenetics-market-1339

Key Players:

Some of the players are Illumina (US), Thermo Fisher Scientific (US), Merck Millipore (US), Abcam (UK), Active Motif (US), Bio-Rad Laboratories (US), New England Biolabs (US), Agilent (US), QIAGEN (Netherlands), Zymo Research (US), PerkinElmer (US), and Diagenode (Belgium).

The Epigenetics market is segmented as follows:

Press Release Content


Contact:
Coralia Joe
Manager
Phone : 1-20) 380-9727
Email : coralia.joe@vantagemarketresearch.com

Top